Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States. METHODS: We analyzed serum samples from four groups of subjects for IgE antibodies against cetuximab: pretreatment samples from 76 case subjects who had been treated with cetuximab at multiple centers, predominantly in Tennessee, Arkansas, and North Carolina; samples from 72 control subjects in Tennessee; samples from 49 control subjects with cancer in northern California; and samples from 341 female control subjects in Boston. RESULTS: Among 76 cetuximab-treated subjects, 25 had a hypersensitivity reaction to the drug. IgE antibodies against cetuximab were found in pretreatment samples from 17 of these subjects; only 1 of 51 subjects who did not have a hypersensitivity reaction had such antibodies (P<0.001). IgE antibodies against cetuximab were found in 15 of 72 samples (20.8%) from control subjects in Tennessee, in 3 of 49 samples (6.1%) from northern California, and in 2 of 341 samples (0.6%) from Boston. The IgE antibodies were shown to be specific for an oligosaccharide, galactose-alpha-1,3-galactose, which is present on the Fab portion of the cetuximab heavy chain. CONCLUSIONS: In most subjects who had a hypersensitivity reaction to cetuximab, IgE antibodies against cetuximab were present in serum before therapy. The antibodies were specific for galactose-alpha-1,3-galactose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Humans also lack the ability to produce the Galα1–3Galβ1–4GlcNAc–R epitope, which is common in murine cells, and this has been shown to induce anaphylaxis [8,33].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003;Chung et al., 2008;Macher and Galili, 2008;Padler-Karavani et al., 2008;Ghaderi et al., 2012).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Chung et al., 2008
Experimental — accuracy not yet measuredIn the citing paper
“However, anti-α-Gal IgE antibodies can cause allergic reactions, such as anaphylaxis, against cetuximab, a therapeutic monoclonal antibody targeting epidermal growth factor receptor (EGFR)”
From ABO blood group antigens and differential glycan expression: Perspective on the evolution of common human enzyme deficiencies (2023) · cites this paper as Chung et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., Hamilton, A., Pan, D., Schrag, D., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.037 · Cited by 1,081
(1945) · Harvard University Press eBooks · doi:10.4159/harvard.9780674184220 · Cited by 1,078
The diagnosis and management of anaphylaxis: An updated practice parameter
LIEBERMAN, P., KEMP, S., OPPENHEIMER, J., LANG, D., BERNSTEIN, I., NICKLAS, R., ANDERSON, J., BERNSTEIN, D., BERNSTEIN, J., & FINK, J. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.010 · Cited by 667
Symposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
The incidence and management of infusion reactions to infliximab: a large center experience
Cheifetz, A. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00231-4 · Cited by 491
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation
Holgate, S., Casale, T., Wenzel, S., Bousquet, J., Deniz, Y., & Reisner, C. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.053 · Cited by 466
Research works printed but not linked: 1
- Carolina; association with atopic history. J Clin Oncol 2007;25:3644-8.
Cited by
Items 601–700 of 1,002
Briggs, J. B., Keck, R. G., Ma, S., Lau, W., & Jones, A. J. S. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.03.006 · Cited by 26
Overcoming immunogenicity associated with the use of biopharmaceuticals
Tovey, M. G., Legrand, J., & Lallemand, C. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.39 · Cited by 24
Emerging antigens involved in allergic responses
Platts‐Mills, T. A. E., & Commins, S. P. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.09.002 · Cited by 26
Self-citationHomann, A., Röckendorf, N., Kromminga, A., Frey, A., Platts‐Mills, T. A. E., & Jappe, U. (2017) · Theranostics · doi:10.7150/thno.20654 · Cited by 24
Self-citationStabach, P. R., Zimmerman, K., Adame, A., Kavanagh, D., Saeui, C. T., Agatemor, C., Gray, S. D., Cao, W., Cruz, E. M. D. L., Yarema, K. J., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12887 · Cited by 24
The Role of Glycosylation in Therapeutic Antibodies
Spearman, M. A., Dionne, B., & Butler, M. (2011) · Cell engineering · doi:10.1007/978-94-007-1257-7_12 · Cited by 30
Burk, C. M., Beitia, R. A., Lund, P. K., & Dellon, E. S. (2015) · Diseases of the Esophagus · doi:10.1111/dote.12356 · Cited by 24
Cetuximab infusion reactions: French pharmacovigilance database analysis
Grandvuillemin, A., Dautriche, A., Miremont‐Salamé, G., Fourrier‐Réglat, A., & Sgro, C. (2012) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212457965 · Cited by 24
B Cell Responses in the Development of Mammalian Meat Allergy
Chandrasekhar, J. L., Cox, K. M., & Erickson, L. D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01532 · Cited by 28
An Overview of the Relevance of IgG4 Antibodies in Allergic Disease with a Focus on Food Allergens
Platts‐Mills, T. A. E., Keshavarz, B., Wilson, J. M., Li, R., Heymann, P. W., Gold, D. R., McGowan, E. C., & Erwin, E. A. (2021) · Children · doi:10.3390/children8050418 · Cited by 26
Self-citationImplementing a Clinical Immunogenicity Strategy using Preclinical Risk Assessment Outputs
Jawa, V., Maamary, J., Swanson, M. D., Zhang, S., & Montgomery, D. L. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.01.032 · Cited by 23
2nd Charles Richet et Jules Héricourt Workshop
Daguet, A., & Watier, H. (2011) · mAbs · doi:10.4161/mabs.3.5.17485 · Cited by 24
Parasitic worms and allergies in childhood: Insights from population studies 2008–2013
Amoah, A. S., Boakye, D. A., van Ree, R., & Yazdanbakhsh, M. (2013) · Pediatric Allergy and Immunology · doi:10.1111/pai.12174 · Cited by 25
Jha, S., Agarwal, S., Sanyal, I., Jain, G. K., & Amla, D. V. (2012) · Plant Science · doi:10.1016/j.plantsci.2012.07.004 · Cited by 23
Ketzer, S., Schimmel, K. J. M., Koopman, M., & Guchelaar, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0590-9 · Cited by 25
Graves‐Deal, R., Bogatcheva, G. T., Rehman, S., Lu, Y., Higginbotham, J. N., & Singh, B. (2019) · Oncotarget · doi:10.18632/oncotarget.26663 · Cited by 27
Alpha‐gal syndrome: An emerging cause of food and drug allergy
Rutkowski, K., Wagner, A., Rutkowski, R., Sowa, P., Pancewicz, S. A., & Moniuszko-Malinowska, A. M. (2020) · Clinical & Experimental Allergy · doi:10.1111/cea.13683 · Cited by 24
Gorovits, B. (2020) · The AAPS Journal · doi:10.1208/s12248-020-00530-4 · Cited by 24
Hypersensitivity and Immune-related Adverse Events in Biologic Therapy
Waldron, J. L., Schworer, S. A., & Kwan, M. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08879-w · Cited by 26
Brennan, F. R., Cauvin, A. J., Tibbitts, J., & Wolfreys, A. (2014) · Drug Development Research · doi:10.1002/ddr.21173 · Cited by 23
Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease
Mounach, A., Rezqi, A., Nouijai, A., Ghozlani, I., Achemlal, L., Maghraoui, A. E., & Bezza, A. (2011) · Rheumatology International · doi:10.1007/s00296-011-2212-4 · Cited by 23
Rizer, J., Brill, K., Charlton, N. P., & King, J. D. (2017) · Clinical Toxicology · doi:10.1080/15563650.2017.1313981 · Cited by 23
Recombinant Proteins and Monoclonal Antibodies
Jefferis, R. (2017) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2017_32 · Cited by 25
Uhler, R., Popa-Wagner, R., Kröning, M., Brehm, A., Rennert, P., Seifried, A., Peschke, M., Krieger, M., Kohla, G., Kannicht, C., et al. (2021) · Glycobiology · doi:10.1093/glycob/cwaa119 · Cited by 24
Anaphylaxis to Excipients in Current Clinical Practice
Bruusgaard‐Mouritsen, M. A., Nasser, S. M., Garvey, L. H., Krantz, M. S., & Stone, C. A. (2022) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2021.12.008 · Cited by 25
Gilstad, C. W., Conry-Cantilena, K., Zarpak, R., & Eder, A. F. (2023) · Transfusion · doi:10.1111/trf.17521 · Cited by 23
Yagi, Y., Kakehi, K., Hayakawa, T., Ohyama, Y., & Suzuki, S. (2012) · Analytical Biochemistry · doi:10.1016/j.ab.2012.09.006 · Cited by 23
The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs
Jefferis, R. (2009) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-26-1 · Cited by 22
Lathuilière, A., Bohrmann, B., Kopetzki, E., Schweitzer, C., Jacobsen, H., Moniatte, M., Aebischer, P., & Schneider, B. L. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.026 · Cited by 24
Fréling, E., Peyrin‐Biroulet, L., Poreaux, C., Morali, A., Waton, J., Schmutz, J. ‐., Guéant, J., & Barbaud, A. M. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000436 · Cited by 23
Glyco-Engineering of Plant-Based Expression Systems
Fischer, R., Holland, T., Sack, M., Schillberg, S., Stöger, E., Twyman, R. M., & Buyel, J. F. (2018) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2018_76 · Cited by 27
Sala-Cunill, A., Luengo, O., & Cardona, V. (2019) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000550 · Cited by 22
Liu, X., Xie, X., Du, H., Sanganyado, E., Wang, W., Aslam, M. A., Chen, J., Chen, W., & Liang, H. (2021) · Algal Research · doi:10.1016/j.algal.2021.102276 · Cited by 26
Utilizing Biologics in Drug Desensitization
Yang, B. C., & Castells, M. (2022) · Current Allergy and Asthma Reports · doi:10.1007/s11882-022-01052-z · Cited by 22
Maï, N. E., Donadio, S., Iss, C., Calabro, V., & Ronin, C. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-327-5_2 · Cited by 22
Tovey, M. G. (2011) · Wiley eBooks · doi:10.1002/9781118075685 · Cited by 22
Dupont, B., Mariotte, D., Dugué, A. E., Clarisse, B., Grellard, J., Babin, E., Chauffert, B., Dakpé, S., Moldovan, C., Bouhier‐Leporrier, K., et al. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13140 · Cited by 24
Bax, H. J., Khiabany, A., Stavraka, C., Pellizzari, G., Hak, C. C. W., Robinson, A., Ilieva, K. M., Woodman, N. L., Naceur‐Lombardelli, C., Gillett, C., et al. (2020) · Allergy · doi:10.1111/all.14245 · Cited by 23
Top‐Down Proteomics: Why and When?
Kaulich, P. T., & Tholey, A. (2025) · PROTEOMICS · doi:10.1002/pmic.202400338 · Cited by 24
Hypersensitivity Reactions to Monoclonal Antibodies in Children
Mori, F., Saretta, F., Bianchi, A., Crisafulli, G., Caimmi, S. M. E., Liotti, L., Bottau, P., Franceschini, F., Paglialunga, C., Ricci, G., et al. (2020) · Medicina · doi:10.3390/medicina56050232 · Cited by 21
Genetic and structural basis of the human anti-α-galactosyl antibody response
Langley, D. B., Schofield, P., Névoltris, D., Jackson, J., Jackson, K., Peters, T. J., Burk, M., Matthews, J. M., Basten, A., Goodnow, C. C., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123212119 · Cited by 21
Th2-skewed T cells correlate with B cell response to α-Gal and tick antigens in α-Gal syndrome
Apostolović, D., Grundström, J., Kiewiet, M. B. G., Peruško, M., Hamsten, C., Starkhammar, M., Paulie, S., & van Hage, M. (2023) · Journal of Clinical Investigation · doi:10.1172/jci158357 · Cited by 23
Tatarewicz, S. M., Juan, G., Swanson, S. J., & Moxness, M. S. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.05.009 · Cited by 22
Szabó, Z., Guttman, A., Bones, J., Shand, R. L., Meh, D. A., & Karger, B. L. (2012) · Molecular Pharmaceutics · doi:10.1021/mp200612n · Cited by 21
Commins, S. P. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0492-y · Cited by 25
Wu, Y., Liu, X., Chen, Y., Woods, R. M., Lee, N., Yang, H., Chowdhury, P. S., Roskos, L. K., & White, W. I. (2013) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2013.06.005 · Cited by 21
Safety profile of new anticancer drugs
Mansi, L., Thiery-Vuillemin, A., Nguyen, T., Bazán, F., Calcagno, F., Rocquain, J., Demarchi, M., Villanueva, C., Maurina, T., & Pivot, X. B. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903530663 · Cited by 22
Biological agents: New drugs, old problems
Muñoz‐Cano, R., Carnés, J., Sánchez-López, J., Saiz, A., Bartra, J., López-Matas, M. A., Picado, C., & Valero, A. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.05.004 · Cited by 21
Tayi, V. S., & Butler, M. (2015) · Journal of Biological Methods · doi:10.14440/jbm.2015.52 · Cited by 22
Weiss, J. M., Olson, J. G., Deal, A. M., Chera, B. S., Weissler, M. C., Murphy, B. A., Hayes, D. N., & Gilbert, J. (2016) · Cancer · doi:10.1002/cncr.29978 · Cited by 24
Self-citationCarlsson, M., Braddock, M., Li, Y., Wang, J., Xu, W., White, N., Megally, A., Hunter, G., & Colice, G. (2019) · Drug Safety · doi:10.1007/s40264-018-00788-w · Cited by 22
Vultaggio, A., Nencini, F., Bormioli, S., Dies, L., Vivarelli, E., Maggi, E., & Matucci, A. (2020) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.12.040 · Cited by 21
Ohyama, Y., Nakajima, K., Renfrow, M. B., Novák, J., & Takahashi, K. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1769479 · Cited by 23
Dickey, T. H., Gupta, R., McAleese, H., Ouahes, T., Orr-Gonzalez, S., Ma, R., Muratova, O. V., Salinas, N. D., Hume, J. C. C., Lambert, L., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00619-9 · Cited by 22
Monoclonal antibodies for targeted therapy in colorectal cancer.
Banerjee, S., & Flores‐Rozas, H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11403 · Cited by 22
Delayed mammalian meat‐induced anaphylaxis confirmed by skin test to cetuximab
Lee, J. H., Kim, J. H., Kim, T. H., & Kim, S. (2013) · The Journal of Dermatology · doi:10.1111/1346-8138.12140 · Cited by 23
Park, N. J., Wang, X., Diaz, A., Goos, D. M., Bock, C., Vaught, J. D., Sun, W., & Strom, C. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071703 · Cited by 21
Saleem, R. A., Cantin, G. T., Wikström, M., Bolton, G., Kuhns, S. T., McBride, H. J., & Liu, J. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02816-w · Cited by 22
Brockow, K. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113101 · Cited by 20
Thacker, S. G., Her, C., Kelley-Baker, L., Ireland, D. D. C., Manangeeswaran, M., Pang, E. S., & Verthelyi, D. I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970499 · Cited by 20
Sauerborn, M., & van Dongen, W. D. (2014) · BioDrugs · doi:10.1007/s40259-014-0096-z · Cited by 20
The Changing Geoepidemiology of Food Allergies
Leung, P. S. C., Shu, S.-A., & Chang, C. C.-C. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8411-5 · Cited by 20
Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
Patel, A. N., Mehnert, J. M., & Kim, S. (2012) · Clinical Medicine Insights Ear Nose and Throat · doi:10.4137/cment.s5129 · Cited by 23
Cancer research meets tick vectors for infectious diseases
Cabezas‐Cruz, A., Valdés, J. J., & de la Fuente, J. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70902-8 · Cited by 22
Lukschal, A., Wallmann, J., Bublin, M., Hofstetter, G., Mothes‐Luksch, N., Breiteneder, H., Pali‐Schöll, I., & Jensen‐Jarolim, E. (2016) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2016.8.2.124 · Cited by 20
Singer, J., Manzano-Szalai, K., Fazekas, J., Thell, K., Lukschal, A., Stremnitzer, C., Roth‐Walter, F., Weghofer, M., Ritter, M., Tossi, K. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1171446 · Cited by 20
Ramesh, M., & Lieberman, P. (2017) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2017.05.014 · Cited by 23
IgE reactivity to α-Gal in relation to Lyme borreliosis
Tjernberg, I., Hamsten, C., Apostolović, D., & van Hage, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185723 · Cited by 22
Wang, J., Dong, X., Yu, A., Huang, Y., Peng, W., & Mechref, Y. S. (2022) · The Analyst · doi:10.1039/d2an00010e · Cited by 20
Zalutumumab in head and neck cancer
Schick, U., Gujral, D. M., Richards, T., Harrington, K. J., & Nutting, C. M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.643864 · Cited by 20
Iwamoto, T., Okamoto, A., Ishinaga, H., Shimizu, K., Gayle, A. A., Arai, N., Takeuchi, K., & Okuda, M. (2016) · Cancer Medicine · doi:10.1002/cam4.658 · Cited by 20
Cunningham, S., Starr, E., Shaw, I., Glavin, J., Kane, M., & Joshi, L. (2012) · Analytical Chemistry · doi:10.1021/ac302587q · Cited by 22
The use of urethral stents for the treatment of urethral strictures.
Yachia, D. (1993) · PubMed · Cited by 24
Severe anaphylaxis caused by intravenous anti‐cancer drugs
Horita, N., Miyagi, E., Mizushima, T., Hagihara, M., Hata, C., Hattori, Y., Hayashi, N., Irie, K., Ishikawa, H., Kawabata, Y., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4252 · Cited by 19
Fadul, C. E., Thakur, A. B., Kim, J.-E., Kassay-McAllister, J., Schalk, D. L., Lopes, M. B. S., Donahue, J., Purow, B. W., Dillon, P. M., Le, T. M., et al. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04564-y · Cited by 19
Kroenke, M. A., Weeraratne, D. K., Deng, H., Sloey, B., Subramanian, R., Wu, B. M., Serenko, M., & Hock, M. B. (2017) · Journal of Immunological Methods · doi:10.1016/j.jim.2017.03.005 · Cited by 19
Hiono, T., Matsuda, A., Wagatsuma, T., Okamatsu, M., Sakoda, Y., & Kuno, A. (2018) · Virology · doi:10.1016/j.virol.2018.11.010 · Cited by 19
Galactose-α-1,3-galactose (alpha-gal) allergy: first pediatric case in a series of patients in Spain
Martin-Lazaro, J., Orjales, R. N., González-Guzmán, L. A., Gonzalez, M. T. B., Boquete, M., & Carballada, F. (2019) · Allergologia et Immunopathologia · doi:10.1016/j.aller.2019.07.004 · Cited by 20
Kobayashi, H., Okada, K., Tokuda, S., Kanao, E., Masuda, Y., Naito, T., Takaya, H., Yan, M., Kubo, T., & Otsuka, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-70904-3 · Cited by 19
Lungulescu, C. V., Ungureanu, B. S., Turcu-Ştiolică, A., Ghimpău, V., Artene, Ş.-A., Cazacu, I. M., Grecu, A. F., Dinescu, V. C., Croitoru, A. E., & Volovăț, S. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-78497-7 · Cited by 19
Biologics for atopic diseases: Indication, side effect management, and new developments
Jappe, U., Beckert, H., Bergmann, K., Gülşen, A., Klimek, L., Philipp, S., Pickert, J., Rauber, M. M., Renz, H. E., Taube, C., et al. (2021) · Allergologie · doi:10.5414/alx02197e · Cited by 25
Alpha-Gal Syndrome in Children: Peculiarities of a “Tick-Borne” Allergic Disease
Saretta, F., Giovannini, M., Mori, F., Arasi, S., Liotti, L., Pecoraro, L., Barni, S., Castagnoli, R., Mastrorilli, C., Caminiti, L., et al. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.801753 · Cited by 22
Woodall, D. W., Dillon, T. M., Kalenian, K., Padaki, R., Kuhns, S. T., Semin, D. J., & Bondarenko, P. V. (2022) · mAbs · doi:10.1080/19420862.2021.2004982 · Cited by 21
Mammalian meat allergy: a diagnostic challenge
Fischer, J., Yazdi, A. S., & Biedermann, T. (2015) · Allergo Journal International · doi:10.1007/s40629-015-0050-8 · Cited by 19
Advances in analytical methodologies to guide bioprocess engineering for bio-therapeutics
Saldova, R., Kilcoyne, M., Stöckmann, H., Millán‐Martín, S., Lewis, A. M., Tuite, C. M. E., Gerlach, J. Q., Berre, M. L., Borys, M., Li, Z. J., et al. (2016) · Methods · doi:10.1016/j.ymeth.2016.11.002 · Cited by 20
Influence of Parasitic Worm Infections on Allergy Diagnosis in Sub-Saharan Africa
Amoah, A. S., Boakye, D. A., Yazdanbakhsh, M., & van Ree, R. (2017) · Current Allergy and Asthma Reports · doi:10.1007/s11882-017-0733-y · Cited by 22
Cox, K. M., Commins, S. P., Capaldo, B. J., Workman, L. J., Platts‐Mills, T. A. E., Amir, E.-A. D., Lannigan, J. A., Schuyler, A. J., & Erickson, L. D. (2018) · Clinical & Experimental Allergy · doi:10.1111/cea.13322 · Cited by 20
Self-citationMonoclonal Antibody Therapy for Cancer
Rader, C. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-980-2_3 · Cited by 19
Cell Culture Processes in Monoclonal Antibody Production
Li, F., Shen, A. Y., & Amanullah, A. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse506 · Cited by 21
A tick-acquired red meat allergy
Khoury, J. K., Khoury, N., Schaefer, D., Chitnis, A., & Hassen, G. W. (2017) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2017.10.044 · Cited by 20
Immunoreaction to xenogenic tissue in cardiac surgery: alpha-Gal and beyond
Calafiore, A. M., Haverich, A., Gaudino, M., Mauro, M. D., Fattouch, K., Prapas, S. N., & Zilla, P. (2022) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezac115 · Cited by 18
Why is there no biosimilar of Erbitux®?
Douez, E., D’Atri, V., Guillarme, D., Antier, D., Guerriaud, M., Beck, A., Watier, H., & Foucault‐Fruchard, L. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115544 · Cited by 19
Food allergy endotypes revisited
Baker, M. G., Wong, L. S. Y., Konstantinou, G. Ν., & Nowak-Wegrzyn, A. H. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.04.019 · Cited by 18
Potential application of Leishmania tarentolae as an alternative platform for antibody expression
Lai, J. Y., Klatt, S., & Lim, T. S. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2019.1566206 · Cited by 20
Immunogenicity of Protein Therapeutics: A Lymph Node Perspective
Fu, K., March, K., Alexaki, A., Fabozzi, G., Moysi, E., & Petrovas, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00791 · Cited by 18
Allergic reactions to tick saliva components in zebrafish model
Contreras, M., Vaz‐Rodrigues, R., Mazuecos, L., Villar, M., Artigas-Jerónimo, S., González-García, A., Shilova, N. V., Bovin, N. V., Sanchez, S. D., Ferreras‐Colino, E., et al. (2023) · Parasites & Vectors · doi:10.1186/s13071-023-05874-2 · Cited by 18
Galactose-Alpha-1,3-Galactose, Mammalian Meat and Anaphylaxis: A World-Wide Phenomenon?
van Nunen, S. (2014) · Current Treatment Options in Allergy · doi:10.1007/s40521-014-0022-0 · Cited by 18
Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas
Le, Q., & Raben, D. (2008) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2008.09.010 · Cited by 18
Self-citationCancer vaccines inducing antibody production: more pros than cons
Jensen‐Jarolim, E., & Singer, J. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.105 · Cited by 18
Hansen, R., Dickson, A. J., Goodacre, R., Stephens, G., & Sellick, C. A. (2010) · Biotechnology and Bioengineering · doi:10.1002/bit.22879 · Cited by 19
Metadata
- Authors
- Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., Slebos, R. J., Zhou, Q., Gold, D., Hatley, T., Hicklin, D. J., & Platts-Mills, T. A. E.
- Affiliations
- Vanderbilt University (US)
- Bristol-Myers Squibb (United States) (US)
- Stanford University (US)
- Duke Medical Center (US)
- University of Virginia (US)
- Harvard University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-03-13
- Volume
- 358
- Issue
- 11
- Pages
- 1109-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2361129
- OpenAlex
- W2140035322
- Cited by
- 1,521
- References
- 35
- Citations by year
- 2026: 63 · 2025: 79 · 2024: 64 · 2023: 83 · 2022: 78 · 2021: 78 · 2020: 94 · 2019: 80 · 2018: 78 · 2017: 109 · 2016: 90 · 2015: 99 · 2014: 88 · 2013: 97 · 2012: 94
- FWCI
- 57.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Damon Runyon Cancer Research Foundation
- Bristol-Myers Squibb
- Vanderbilt University
- Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation
- National Institutes of Health (20565, 2r01ai020565-29, 5r01ca118582-05, AI-20565)
- U.S. Public Health Service (AI-AADCRC-U19-070364)
- National Cancer Institute (R01-CA-118582, P50CA095103, P50CA95103)
- National Institute of Allergy and Infectious Diseases (AI 20565, R01AI035796, R01AI-020565, AI/EHS-35796, R29AI035796, R37AI020565)
- National Institute of Dental and Craniofacial Research (R01DE017982)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Keywords
- cetuximab, anaphylaxis, drug hypersensitivity, IgE antibodies, galactose-alpha-1,3-galactose, Fab fragment, monoclonal antibodies, epidermal growth factor receptor, pre-existing antibodies, colorectal cancer, head and neck squamous cell carcinoma
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Anaphylaxis, Antibodies, Monoclonal, Epitopes, Antineoplastic Agents, Cross Reactions, Disaccharides, Female, Humans, Immunoglobulin E, Male, Middle Aged, Protein Binding, Protein Conformation, Case-Control Studies, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.